Literature DB >> 8226879

Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments.

H K Paudel1, J Lew, Z Ali, J H Wang.   

Abstract

Brain proline-directed protein kinase (BPDK), which contains a catalytic subunit homologous to and displaying site-specific phosphorylation similar to p34cdc2 kinase (Lew, J., Winkfein, R. J., Paudel, H. K., and Wang, J. H. (1992) J. Biol. Chem. 267, 25922-25926), has been examined for possible involvement in tau phosphorylation. Immunoblot analyses using peptide antibodies specific for BPDK have revealed the presence of the kinase in bovine brain microtubules purified extensively by repeated polymerization and depolymerization cycles. When the microtubule proteins are separated into the tubulin and microtubule-associated protein fractions, BPDK is found exclusively in the latter fraction. BPDK phosphorylates both tau and MAP2, the former protein being phosphorylated to a stoichiometry of 3.8 mol of phosphate/mol of tau. Analysis of the phosphopeptides isolated from the tryptic digest of the phosphorylated bovine tau has revealed seven phosphorylation sites. Based on the sequence alignment between bovine and human tau proteins, these sites correspond to Ser-195, Ser-202, Thr-205, Thr-231, Ser-235, Ser-396, and Ser-404 of human tau. Mass spectrometric analysis of the tau protein isolated from Alzheimer's paired helical filaments (PHFs) has determined three abnormal phosphorylation sites and two phosphopeptides containing a total of five abnormal phosphates (Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., and Ihara, Y. (1992) J. Biol. Chem. 267, 17047-17054). Two of the sites in tau phosphorylated by BPDK, Thr-231 and Ser-235, are among the abnormal phosphorylation sites, and the other sites phosphorylated by BPDK are within phosphopeptides from PHF-tau. These results suggest that BPDK may be one of the kinases responsible for the abnormal phosphorylation-associated PHF-tau.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8226879

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Integrin alpha(1) beta(1)-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation.

Authors:  B S Li; L Zhang; J Gu; N D Amin; H C Pant
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain.

Authors:  I Vincent; G Jicha; M Rosado; D W Dickson
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

3.  Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.

Authors:  Nimrod Miller; Zhihua Feng; Brittany M Edens; Ben Yang; Han Shi; Christie C Sze; Benjamin Taige Hong; Susan C Su; Jorge A Cantu; Jacek Topczewski; Thomas O Crawford; Chien-Ping Ko; Charlotte J Sumner; Long Ma; Yong-Chao Ma
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

4.  Effect of GAPT extract on expression of tau protein and its phosphorylation related enzymes in hippocampal neurons of APPV717I transgenic mice.

Authors:  Jing-Nian Ni; Jing Shi; Xue-Kai Zhang; Yi-Chang Yang; Xiao-Meng Liu; Ming-Qing Wei; Ting Li; Peng-Wen Wang; Jin-Zhou Tian; Yong-Yan Wang
Journal:  Chin J Integr Med       Date:  2017-06-20       Impact factor: 1.978

5.  Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.

Authors:  M K Ahlijanian; N X Barrezueta; R D Williams; A Jakowski; K P Kowsz; S McCarthy; T Coskran; A Carlo; P A Seymour; J E Burkhardt; R B Nelson; J D McNeish
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

6.  Effect of human neuronal tau on denaturation and reactivation of rabbit muscle D-glyceraldehyde-3-phosphate dehydrogenase.

Authors:  Y H Chen; R Q He; Y Liu; Y Liu; Z G Xue
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

Review 7.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

8.  Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.

Authors:  Patrice D Smith; Stephen J Crocker; Vernice Jackson-Lewis; Kelly L Jordan-Sciutto; Shawn Hayley; Matthew P Mount; Michael J O'Hare; Steven Callaghan; Ruth S Slack; Serge Przedborski; Hymie Anisman; David S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

9.  Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms.

Authors:  C Laura Sayas; Jesús Avila; Francisco Wandosell
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  Phosphorylation sensitizes microtubule-associated protein tau to Al(3+)-induced aggregation.

Authors:  W Li; K K Ma; W Sun; H K Paudel
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.